THE RESULTS OF TREATMENT OF GIANT CELL TUMOR OF LONG BONES WITH DENOSUMAB

Authors

  • Anatolii Diedkov National Cancer Institute, Kiev. Ukraine, Ukraine
  • Bogdan Maksimenko National Cancer Institute, Kiev. Ukraine, Ukraine

DOI:

https://doi.org/10.15674/0030-59872021359-64

Keywords:

Giant cell tumor, denosumab, relaps, omplications

Abstract

Surgical intervention remains a gold standard for the treatment of giant cell tumors (GCT) of long bones. The significant risk of recurrence after the curettage and a high complication rate after radical resections is still an unsolved problem. Targeted therapy with denosumab could solve this problem in favor of curettage, but recent studies have shown negative results with denosumab in such situation. Objective. To analyze the results of the denosumab application in patients with long bone GCP with indications for joint salvage surgery. Methods. We compared the treatment results in two groups
of patients: 1st retrospective (control) group — 57 patients, who underwent curettage with surgical treatment and the 2nd prospective (main) group — 42 patients with combination of surgery with neoadjuvant and adjuvant denosumab tretment. In the 2nd group of patients received 5 neoadjuvant and 5 adjuvant cycles of denosumab. The median follow-up period was 189 months in the control group, and 45 months in the main group. Results. Disease progression which identified as a local recurrence was revealed in the control group in 15 patients (25.4 %) and in 7 patients (16.7 %) in the main
group (p = 0.19). In the main group, the median time to relapse was 19.8 months (8–34 months) from the date of surgery, in the control group — 15.1 months (9–28 months), respectively. The statistically significant difference in relapse-free survival (RFS) between patients in the main group and in the control group (p = 0.18) was not revealed. But the 5-year RFS in the main group was higher and reached to 85 % (95 % CI 74–96 %) versus 75 % (95 % CI 64–86 %) in control group, respectively. There was no evidence of malignant transformation in the main group and one case in retrospective group. Conclusions. The application of denosumab in the regimen before and after curettage is associated with lees number of relapses — 16.7 % vs. 25.4 % without denosumab, respectively. The lack of statistically significant difference between groups does not provide the sufficient reasons for denosumab prescription in neoadjuvant regimen. But adjuvant administration of denosumab can be considered as preventing factor of recurrence after primary tumor curettage, which may be perspective for further study and optimization of indications for its application in patients with GCT.

Author Biographies

Anatolii Diedkov, National Cancer Institute, Kiev. Ukraine

MD, Prof. in Traumatology and Orthopаedics

Bogdan Maksimenko, National Cancer Institute, Kiev. Ukraine

MD

References

  1. Van der Heijden, L., Dijkstra, P. S., Blay, J., & Gelderblom, H. (2017). Giant cell tumour of bone in the denosumab era. European Journal of Cancer, 77, 75-83. https://doi.org/10.1016/j.ejca.2017.02.021
  2. Kato, I., Furuya, M., Matsuo, K., Kawabata, Y., Tanaka, R., & Ohashi, K. (2018). Giant cell tumours of bone treated with denosumab: Histological, immunohistochemical and H3F3A mutation analyses. Histopathology, 72(6), 914-922. https://doi.org/10.1111/his.13448
  3. Atkins, G. J., Haynes, D. R., Graves, S. E., Evdokiou, A., Hay, S., Bouralexis, S., & Findlay, D. M. (2010). Expression of osteoclast differentiation signals by Stromal elements of giant cell tumors. Journal of Bone and Mineral Research, 15(4), 640-649. https://doi.org/10.1359/jbmr.2000.15.4.640
  4. Vyrva, O. E., & Skoryk, I. O. (2019). Modular endoprosthesis of the proximal tibia in the case of a giant cell tumor. Orthopedics, traumatology and prosthetics, (1), 72–77. https://doi.org/10/15674/0030-59872019172-77. [in Ukrainian]
  5. Chawla, S., Blay, J., Rutkowski, P., Le Cesne, A., Reichardt, P., Gelderblom, H., ... & Palmerini, E. (2019). Denosumab in patients with giant-cell tumour of bone: A multicentre, open-label, phase 2 study. The Lancet Oncology, 20(12), 1719-1729. https://doi.org/10.1016/s1470-2045(19)30663-1
  6. Traub, F., Singh, J., Dickson, B. C., Leung, S., Mohankumar, R., Blackstein, M. E., ... & Wunder, J. S. (2016). Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone. European Journal of Cancer, 59, 1-12. https://doi.org/10.1016/j.ejca.2016.01.006
  7. Scoccianti, G., Totti, F., Scorianz, M., Baldi, G., Roselli, G., Beltrami, G., ... & Campanacci, D. A. (2018). Preoperative Denosumab with curettage and cryotherapy in giant cell tumor of bone: Is there an increased risk of local recurrence? Clinical Orthopaedics & Related Research, 476(9), 1783-1790. https://doi.org/10.1007/s11999.0000000000000104
  8. Puri, A., Gulia, A., Hegde, P., Verma, V., & Rekhi, B. (2019). Neoadjuvant denosumab. The Bone & Joint Journal, 101-B(2), 170-177. https://doi.org/10.1302/0301-620x.101b2.bjj-2018-0907.r2
  9. Campanacci, M., Baldini, N., Boriani, S., & Sudanese, A. (1987). Giant-cell tumor of bone. The Journal of Bone & Joint Surgery, 69(1), 106-114. https://doi.org/10.2106/00004623-198769010-00018
  10. Zou, C., Lin, T., Wang, B., Zhao, Z., Li, B., Xie, X., ... & Shen, J. (2019). Managements of giant cell tumor within the distal radius: A retrospective study of 58 cases from a single center. Journal of Bone Oncology, 14, 100211. https://doi.org/10.1016/j.jbo.2018.100211
  11. Guryanov, V. G., Lyakh, Y. E., & Pariy, V. D. (2018). Analysis of the results of medical research in the package EZR (R-statistics). Manual on biostatistics: textbook. Manual. Kyiv: Vistka. [in Ukrainian]
  12. Errani, C., Tsukamoto, S., Leone, G., Righi, A., Akahane, M., Tanaka, Y., & Donati, D. M. (2018). Denosumab may increase the risk of local recurrence in patients with giant-cell tumor of bone treated with curettage. Journal of Bone and Joint Surgery, 100(6), 496-504. https://doi.org/10.2106/jbjs.17.00057
  13. Agarwal, M. G., Gundavda, M. K., Gupta, R., & Reddy, R. (2018). Does Denosumab change the giant cell tumor treatment strategy? Lessons learned from early experience. Clinical Orthopaedics & Related Research, 476(9), 1773-1782. https://doi.org/10.1007/s11999.0000000000000243

Downloads

How to Cite

Diedkov, A. ., & Maksimenko, B. . (2023). THE RESULTS OF TREATMENT OF GIANT CELL TUMOR OF LONG BONES WITH DENOSUMAB. ORTHOPAEDICS TRAUMATOLOGY and PROSTHETICS, (3), 59–64. https://doi.org/10.15674/0030-59872021359-64

Issue

No. 3 (2021)

Section

ORIGINAL ARTICLES

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The authors retain the right of authorship of their manuscript and pass the journal the right of the first publication of this article, which automatically become available from the date of publication under the terms of Creative Commons Attribution License, which allows others to freely distribute the published manuscript with mandatory linking to authors of the original research and the first publication of this one in this journal.

Authors have the right to enter into a separate supplemental agreement on the additional non-exclusive distribution of manuscript in the form in which it was published by the journal (i.e. to put work in electronic storage of an institution or publish as a part of the book) while maintaining the reference to the first publication of the manuscript in this journal.

The editorial policy of the journal allows authors and encourages manuscript accommodation online (i.e. in storage of an institution or on the personal websites) as before submission of the manuscript to the editorial office, and during its editorial processing because it contributes to productive scientific discussion and positively affects the efficiency and dynamics of the published manuscript citation (see The Effect of Open Access).